Apyx Medical Corp 8-K

What Happened Apyx Medical Corporation (APYX) announced on May 14, 2026 (via an 8-K and attached press release) that a new retrospective investigator‑initiated study has been published in Plastic and Reconstructive Surgery - Global Open. The study evaluated patient‑reported outcomes after liposuction performed with and without helium plasma radiofrequency (Renuvion®).

Key Details

• Filing date: May 14, 2026; press release attached as Exhibit 99.1 to the Form 8‑K.
• Publication: Study appeared in the journal Plastic and Reconstructive Surgery - Global Open.
• Study type: Retrospective, investigator‑initiated; compared patient‑reported outcomes for liposuction with vs. without Renuvion (helium plasma radiofrequency).
• The 8‑K reports the press release only; no financial results, management changes, or other material disclosures were included.

Why It Matters This filing documents the publication of clinical evidence related to Apyx’s Renuvion technology, which can influence clinician adoption, marketing, and investor perception of the product’s utility in cosmetic/reconstructive procedures. The 8‑K itself does not provide new financial data or operational metrics, but investors may view peer‑reviewed study publications as supportive for long‑term commercial prospects.